Skip to main content
Fig. 1 | BMC Gastroenterology

Fig. 1

From: Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China

Fig. 1

Patient diagram for long-term follow-up study following the P05170 multicenter randomized trial. In the long-term follow-up (LTFU), 93.6% (615/657) of subjects from PEG-IFN alpha-2b therapy were contacted by a telephone interview. Of the 615 subjects contacted, 34.0% (209/615) of subjects failed to connect, 13.7% (84/615) declined the LTFU. Hence, a total of 322 subjects had a site visit after the telephone interview, and completed the study. The overall LTFU rate for the study was 49.0% (322/657). No subject (0/322) withdrew during the LTFU study. *One patient received no study medication after randomization. “Lost contact” indicates the investigators did not have any contact information on the subject from P05170, and “Telephone visit failed” indicates patients who were called but no one answered the phone or the number was incorrect

Back to article page